Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers.
Journal: The oncologist
Published: January 21, 2026
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.
Journal: Journal for immunotherapy of cancer
Published: December 23, 2025
"A lot of the times, patients really don't know what questions to ask:" Communication perspectives of Black patients with advanced lung cancer.
Journal: Patient education and counseling
Published: October 22, 2025
First-in-human study of the dual A2A/A2B adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors.
Journal: ESMO open
Published: October 15, 2025
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 23, 2025
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.
Journal: Cell reports. Medicine
Published: July 17, 2025
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 19, 2025
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial.
Journal: The Lancet. Oncology
Published: March 03, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Journal: Cancer research communications
Published: February 12, 2025
Feasibility and Acceptability of Symptom Management Research in Black Advanced Lung Cancer Patients.
Feasibility and Acceptability of Symptom Management Research in Black Advanced Lung Cancer Patients.
Journal: Journal of pain and symptom management
Published: February 12, 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: January 16, 2025
Editorial: Towards the embedding of artificial intelligence into synthetic organisms: engineering intelligence in microorganisms.
Journal: Frontiers in genetics
Published: January 16, 2025
Last Updated: 09/26/2026